No reaction
No reactiondose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Zolpidem
N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide
Ambien, Intermezzo, Edluar, Stilnoct, Stilnox
Zolpidem is a nonbenzodiazepine hypnotic of the imidazopyridine class, first approved by the FDA in 1992 for the treatment of insomnia.citation needed It acts at the GABA-BZ receptor complex, sharing pharmacological properties with benzodiazepines while producing comparatively less anxiolysis, muscle relaxation, and anticonvulsant activity. At higher doses, zolpidem can produce realistic hallucinations resembling those of deliriants, significant amnesia, and marked disinhibition.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~2.5 mg
Light2.5-5 mg
Moderate5-10 mg
Strong10-20 mg
Heavy20+ mg
Bioavailability
~70%
Associated with complex sleep behaviors, in which activities are performed during sleep and followed by amnesia. Sedation and impairment may persist for up to 7 hours after hypnotic-range doses.
Duration
Onset15-45 minutes
Come Up30-45 minutes
Peak3-6 hours
Offset4-5 hours
After Effects1-24 hours
Total5-10 hours
Half-life
2-3 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
At standard medical doses, the experience consists of little beyond sedation, with drowsiness, decreased alertness, and dizziness dominating and negative effects remaining mild. At common to strong doses, the character of the experience can shift considerably, with reports of euphoria, open- and closed-eye visuals, and realistic hallucinations comparable to those of deliriants. Anterograde amnesia becomes very likely at higher doses, and inhibitions can be lowered to the point that users act in ways they would not while sober.
Physical
The body experience centers on heavy somnolence and sedation alongside dizziness and reduced psychomotor performance and coordination. Impairment can persist into the following day, particularly at higher doses or with extended-release formulations.
Sedation
Central nervous system depression is the core physical effect and the basis of the drug's hypnotic use.
Cognitive
The headspace is dominated by sedation and impaired recall; memory of events during peak effects is frequently partial or absent at doses above 10 mg. Euphoria and anxiety relief occur only inconsistently, while lowered inhibitions and delusional thinking are reported at higher doses.
Emotional
Positive emotional effects are inconsistent and dose-dependent.
Libidinal
Suppressions
Visual
Closed- and open-eye visuals are rarely noted at 10 mg and appear more often, though still unreliably, at common to strong doses.
Hallucinatory States
Pharmacology
Pharmacodynamics
Zolpidem acts as a positive allosteric modulator at GABAA receptors, binding at the benzodiazepine site to enhance GABAergic inhibition in the central nervous system.1 It exhibits pronounced selectivity for GABAA receptors containing the α1 subunit, with approximately 10-fold lower affinity for α2- and α3-containing receptors and no appreciable affinity for those containing the α5 subunit.citation needed This subunit selectivity confers strong hypnotic properties with comparatively weak anxiolytic, myorelaxant, and anticonvulsant activity.
Pharmacokinetics
Zolpidem is rapidly absorbed from the gastrointestinal tract with an absolute oral bioavailability of approximately 70%,citation needed reaching peak plasma concentrations within roughly 1.6 to 2 hours.1 The elimination half-life in healthy adults is approximately 2 to 3 hours.1 Hepatic metabolism is the primary route of elimination, predominantly via CYP3A4 (approximately 61%), with contributions from CYP2C9 (22%), CYP1A2 (14%), and minor involvement of CYP2D6 and CYP2C19 (each less than 3%).2 Less than 1% of the drug is excreted unchanged in urine, and all three principal metabolites are pharmacologically inactive.citation needed
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
1,2-BenzodiazepineAbametapirAbataceptAbirateroneAbrocitinib
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Zolpidem demonstrates a favorable tolerability profile with low risk of tolerance development when used according to prescribing guidelines. Clinical studies have shown maintained efficacy in decreasing sleep latency for up to 35 days of continuous use.
Cross Tolerance
Benzodiazepines, Other GABA-A receptor positive allosteric modulators, Z-drugs (nonbenzodiazepine hypnotics)
Harm Potential
Addiction & Dependence
Psychological
ModerateZolpidem misuse has been associated with dependence and addiction, often driven by its euphoric effects.3 A 2014 review found evidence of drug-seeking behavior, with zolpidem prescriptions making up 20% of falsified or forged prescriptions. Recreational use is more prevalent in those with a history of drug dependence, though addiction can develop in individuals without such history.
Physical
ModeratePhysical dependence develops with prolonged use, producing withdrawal symptoms resembling benzodiazepine withdrawal.citation needed Abrupt discontinuation may cause tremors, delirium, irritability, and in severe cases, seizures. Reported cases of high-dose dependence document daily doses up to 6,000 mg, with tapering or benzodiazepine substitution typically required for discontinuation.
Toxicity
Central Nervous System
CNS depressant effects including somnolence, respiratory depression, and impaired consciousness occur during intoxication; organ toxicity is rare even at high doses, though severe CNS effects can occur with overdose or extreme use.citation needed
Cognitive/Memory
Anterograde amnesia may occur, particularly at doses above 10 mg; a marked reduction in next-morning recall of information relayed during peak drug effect has been observed in controlled studies.citation needed
Carcinogenicity
Possible
Two-year animal studies showed no evidence of carcinogenicity in mice; renal tumors observed in rats were attributed to spontaneous occurrence.citation needed Zolpidem showed no mutagenic activity in multiple genotoxicity assays.4 However, a 2017 meta-analysis of epidemiological studies found zolpidem use associated with a 34% increased cancer risk, though results were tentative due to confounding factors including smoking and alcohol use.citation needed
Evidence Basis
Human EpidemiologicalLimited
Animal Models
Negative
(rat, mouse)
In Vitro
non-genotoxic
Ames test, mouse lymphoma cells, chromosomal aberration assay, micronucleus test
MechanisticNone
Psychosis Risk
Hallucinations through multiple senses and delusions are reported, particularly at higher doses.citation needed Complex sleep behaviors with amnesia are well-documented.4 Delirium may occur during withdrawal from chronic use.citation needed Visual hallucinations have been noted more frequently when zolpidem is combined with antidepressants.
Seizure Risk
Seizures are primarily a withdrawal risk rather than an acute effect.citation needed Abrupt discontinuation after prolonged use or high doses may cause seizures, particularly in chronic users who have developed physical dependence. Gradual dose reduction is recommended to minimize this risk.
History & Culture
Development and Approval
Zolpidem entered clinical use in Europe in 1988 through the pharmaceutical company Synthelabo. Following its European introduction, Synthelabo collaborated with Searle to pursue regulatory approval in the United States. The FDA granted approval in 1992, and the drug was marketed under the brand…
Legality
By Country
Controlled / restricted1
NetherlandsRestrictedOpiumwet, List II15
The current consolidated Opiumwet lists zolpidem in List II. Article 3 prohibits importing/exporting, preparing, processing, selling, supplying, providing, transporting, possessing, or manufacturing List II substances, subject to statutory exceptions. The Act does not itself establish a product-specific prescription-dispensing status.
Prescription10
AustraliaPrescription onlyPoisons Standard, Schedule 410
Zolpidem is included in Schedule 4 of Australia's Poisons Standard. Schedule 4 substances are prescription-only medicines.
CanadaPrescription onlyBenzodiazepines and Other Targeted Substances Regulations11
Zolpidem is a targeted substance under the federal benzodiazepines and other targeted substances regime. It is available as a prescription medicine and is subject to the regulation's controls on possession and distribution.
IndiaPrescription onlyDrugs and Cosmetics Rules, 194512
Zolpidem is listed in Schedule X to the Drugs and Cosmetics Rules, 1945. A Schedule X drug may be supplied only on the prescription of a registered medical practitioner, and the supplier must record the supply in the prescribed register at the time of supply.
IrelandPrescription onlyMisuse of Drugs Regulations 201713
Zolpidem is regulated as a controlled prescription medicine under Ireland's misuse-of-drugs regulations. The 2017 regulations apply the controlled-drug regime to Z-drug sleeping tablets including zolpidem.
ItalyPrescription onlyDPR 309/1990, Tabella dei medicinali14
Zolpidem is included in Italy's table of narcotic and psychotropic medicines. It is regulated as a prescription medicine rather than placed in the prohibited-substances tables.
PolandPrescription onlyRozporządzenie Ministra Zdrowia w sprawie wykazu substancji psychotropowych16
Zolpidem is listed in Poland's group IV-P psychotropic-substances schedule. It is a controlled prescription medicine under the national narcotics framework.
PortugalPrescription onlyDecreto-Lei n.º 15/93, Tabela IV17
Zolpidem is listed in Portugal's table IV of controlled psychotropic substances. It is provided through the prescription-medicine system under that framework.
SpainPrescription onlyOrden SCO/469/2002; Real Decreto 2829/1977, annex I list IV18
Zolpidem is included in list IV of annex I to Spain's psychotropic-substances regulation. It is regulated as a prescription psychotropic medicine.
SwitzerlandPrescription onlyBetäubungsmittelverzeichnisverordnung19
Zolpidem is a controlled substance under Swiss narcotics law. It is supplied as a prescription medicine under the applicable control framework.
United KingdomPrescription onlyMisuse of Drugs Regulations 2001, Schedule 4 Part I20
Zolpidem is a Class C controlled drug in Schedule 4 Part I of the Misuse of Drugs Regulations. It is supplied lawfully as a prescription medicine subject to the controls applicable to that schedule.
Legal / decriminalized1
References
Source Pages
Citations
- AMBIEN (zolpidem tartrate) Prescribing Information. sanofi-aventis U.S. LLC (2022-02). https://products.sanofi.us/ambien/ambien.pdf1234567
- Lisa L. Von Moltke, David J. Greenblatt, Brian W. Granda, Su Xiang Duan, Jeffrey M. Grassi, Karthik Venkatakrishnan, Jerold S. Harmatz, & Richard I. Shader. (July 1999). Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology, 48(1), 89–97. https://doi.org/10.1046/j.1365-2125.1999.00953.x1
- Fangfei Xie, Bo Liu, Liqiu Yang, Junqiang Huang, Bin Li, & Yuanyuan Li. (November 2024). Zolpidem-related euphoria, addiction and detoxification: A case report and review of the literature. Medicine, 103(44). https://doi.org/10.1097/md.00000000000402801
- Ambien- zolpidem tartrate tablet, film coated. DailyMed (29 August 2019). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452123
- Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. PMC / Journal of Clinical Sleep Medicine (2017). https://pmc.ncbi.nlm.nih.gov/articles/PMC5423710/1
- Zolpidem Drug Usage Statistics, United States, 2014–2023. ClinCalc (n.d.). https://clincalc.com/DrugStats/Drugs/Zolpidem1
- Kennedy's Crash Highlights Dangers of Ambien. ABC News (5 May 2006). https://abcnews.go.com/Health/story?id=1927026&page=11
- Now Roseanne Is Blaming Her Racist Tirade on Ambien. Vice (2018). https://www.vice.com/en/article/roseanne-barr-racist-tweet-ambien-valerie-jarrett-vgtrn/12
- Aussie swimmers admit using sedative. China Daily (via Reuters/AFP) (2013). https://www.chinadaily.com.cn/sports/2013-02/22/content_16249313.htm1
- Poisons Standard, Schedule 4. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00060/asmade/2026-01-30/text/original/epub/OEBPS/document_1/document_1.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Zolpidem article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
